All Outputs (6)

Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service (2024)
Journal Article
Radford, S. J., Abdul-Aema, B., Tench, C., Leighton, P., Coad, J., & Moran, G. W. (2024). Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service. Scandinavian Journal of Gastroenterology, https://doi.org/10.1080/00365521.2024.2330588

Background: Imaging is used to monitor disease activity in small bowel Crohn’s disease (CD). Magnetic Resonance Enterography is often employed as a first modality in the United Kingdom for assessment and monitoring; however, waiting times, cost, pati... Read More about Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service.

Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review (2024)
Journal Article
Egiz, A. M. A. M., Sinopoulou, V., Abousaleh, Gordon, M., Moran, G. W., Phlananthachai, S., …Al-Tameemi, A. H. A. (2024). Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review. BMJ Open Gastroenterology, 11(1), Article e001334. https://doi.org/10.1136/bmjgast-2023-001334

Introduction Randomised controlled trials (RCTs) of key therapies in inflammatory bowel disease (IBD) are often presented and available as abstracts for significant periods of time prior to full publication, often being employed to make strategic and... Read More about Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review.

Infliximab for maintenance of medically-induced remission in Crohn's disease (2024)
Journal Article
Gordon, M., Sinopoulou, V., Sarian, A., Akobeng, A. K., & Moran, G. W. (2024). Infliximab for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews, 2(2), Article CD012609. https://doi.org/10.1002/14651858.CD012609.pub2

BACKGROUND: Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor-alpha (TNF-α) which is present in high levels in the blood serum, mucosa and stool of patients with Crohn's disease. OBJECTIVES: To determine the effica... Read More about Infliximab for maintenance of medically-induced remission in Crohn's disease.

Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial (2024)
Journal Article
Jairath, V., Zou, G., Wang, Z., Adsul, S., Colombel, J., D’Haens, G. R., …Feagan, B. G. (2024). Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterology, 11(1), Article e001218. https://doi.org/10.1136/bmjgast-2023-001218

Introduction: Symptoms, endoscopy and histology have been proposed as therapeutic targets in ulcerative colitis (UC). Observational studies suggest that the achievement of histologic remission may be associated with a lower risk of complications, com... Read More about Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial (2024)
Journal Article
Lindsay, J. O., Hind, D., Swaby, L., Berntsson, H., Bradburn, M., Bannur C, U., …Snowden, J. A. (2024). Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9(4), 333-345. https://doi.org/10.1016/s2468-1253%2823%2900460-0

Background: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy... Read More about Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.

Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study (2024)
Journal Article
Azam, A. S., Tsang, Y., Thirlwall, J., Kimani, P. K., Sah, S., Gopalakrishnan, K., …Snead, D. R. J. (2024). Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study. Histopathology, 84(5), 847-862. https://doi.org/10.1111/his.15129

Aims: To conduct a definitive multicentre comparison of digital pathology (DP) with light microscopy (LM) for reporting histopathology slides including breast and bowel cancer screening samples. Methods: A total of 2024 cases (608 breast, 607 GI, 6... Read More about Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study.